IL296631A - phd inhibitory compounds, compositions and use - Google Patents

phd inhibitory compounds, compositions and use

Info

Publication number
IL296631A
IL296631A IL296631A IL29663122A IL296631A IL 296631 A IL296631 A IL 296631A IL 296631 A IL296631 A IL 296631A IL 29663122 A IL29663122 A IL 29663122A IL 296631 A IL296631 A IL 296631A
Authority
IL
Israel
Prior art keywords
compound
formula
alkyl
pharmaceutically acceptable
hydrogen
Prior art date
Application number
IL296631A
Other languages
English (en)
Hebrew (he)
Inventor
Paul E Fleming
Thomas P Blaisdell
Senkara Rao Allu
Original Assignee
Akebia Therapeutics Inc
Paul E Fleming
Thomas P Blaisdell
Senkara Rao Allu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc, Paul E Fleming, Thomas P Blaisdell, Senkara Rao Allu filed Critical Akebia Therapeutics Inc
Publication of IL296631A publication Critical patent/IL296631A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL296631A 2020-03-20 2021-03-19 phd inhibitory compounds, compositions and use IL296631A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062992585P 2020-03-20 2020-03-20
PCT/US2021/023219 WO2021188936A1 (en) 2020-03-20 2021-03-19 Phd inhibitor compounds, compositions, and use

Publications (1)

Publication Number Publication Date
IL296631A true IL296631A (en) 2022-11-01

Family

ID=75639962

Family Applications (1)

Application Number Title Priority Date Filing Date
IL296631A IL296631A (en) 2020-03-20 2021-03-19 phd inhibitory compounds, compositions and use

Country Status (13)

Country Link
US (1) US20230227426A1 (cg-RX-API-DMAC10.html)
EP (1) EP4121425A1 (cg-RX-API-DMAC10.html)
JP (2) JP7768890B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220156889A (cg-RX-API-DMAC10.html)
CN (2) CN115551845B (cg-RX-API-DMAC10.html)
AR (1) AR121618A1 (cg-RX-API-DMAC10.html)
AU (1) AU2021239378A1 (cg-RX-API-DMAC10.html)
BR (1) BR112022018877A2 (cg-RX-API-DMAC10.html)
CA (1) CA3176140A1 (cg-RX-API-DMAC10.html)
CO (1) CO2022014490A2 (cg-RX-API-DMAC10.html)
IL (1) IL296631A (cg-RX-API-DMAC10.html)
MX (1) MX2022011123A (cg-RX-API-DMAC10.html)
WO (1) WO2021188936A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
US12612367B2 (en) 2019-12-10 2026-04-28 Akebia Therapeutics, Inc. Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative
AR121626A1 (es) 2020-03-20 2022-06-22 Akebia Therapeutics Inc Compuestos inhibidores de phd, composiciones y métodos de uso

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
DE102006050515A1 (de) 2006-10-26 2008-04-30 Bayer Healthcare Ag Substituierte Dipyridiyl-dihydropyrazolone und ihre Verwendung
US8987461B2 (en) 2012-12-06 2015-03-24 Quanticel Pharmaceuticals, Inc. Histone demethylase inhibitors
AP2015008783A0 (en) * 2013-03-29 2015-10-31 Takeda Pharmaceutical 6-(5-hydroxy-1h-pyrazol-1-yl) nicotinamida derivatives and their use as phd inhibitors

Also Published As

Publication number Publication date
CN115551845B (zh) 2025-02-28
CA3176140A1 (en) 2021-09-23
CN115551845A (zh) 2022-12-30
MX2022011123A (es) 2023-01-04
AR121618A1 (es) 2022-06-22
EP4121425A1 (en) 2023-01-25
KR20220156889A (ko) 2022-11-28
CO2022014490A2 (es) 2022-10-21
JP2026021443A (ja) 2026-02-10
JP7768890B2 (ja) 2025-11-12
US20230227426A1 (en) 2023-07-20
JP2023518953A (ja) 2023-05-09
WO2021188936A1 (en) 2021-09-23
CN119823097A (zh) 2025-04-15
BR112022018877A2 (pt) 2022-11-29
AU2021239378A1 (en) 2022-11-17
TW202140443A (zh) 2021-11-01

Similar Documents

Publication Publication Date Title
JP7856575B2 (ja) Phd阻害剤化合物、組成物、及びそれらの使用
WO2019101086A1 (zh) 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
JP2026021443A (ja) Phd阻害剤化合物、組成物、および使用
JP2008523103A (ja) Erkプロテインキナーゼのピリミジンインヒビターおよびその使用
WO2021188938A1 (en) Phd inhibitor compounds, compositions, and use
JP7832179B2 (ja) Phd阻害剤化合物、組成物、及び使用方法
BR122025027331A2 (pt) Compostos, composição farmacêutica e uso
US20240336568A1 (en) Selective phd1 inhibitor compounds, compositions, and methods of use
BR122025027329A2 (pt) Compostos, composição farmacêutica e uso
WO2025137158A1 (en) Derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate as phd inhibitor compounds, compositions, and methods of use
KR20240005892A (ko) Lpa 수용체 길항제 및 이의 용도
CN112384506A (zh) 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用